Paul Tudor Jones's SUPN Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 24,746 shares of Supernus Pharmaceuticals, Inc. (SUPN) worth $1.15 M, representing 0.00% of the portfolio. First purchased in 2014-Q4, this long-term strategic position has been held for 35 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in SUPN, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2021, adding 57,797 shares. Largest reduction occurred in Q1 2023, reducing 36,801 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Supernus Pharmaceuticals (SUPN) Holding Value Over Time
Track share changes against reported price movement
Quarterly Supernus Pharmaceuticals (SUPN) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +24,746 | New Buy | 24,746 | $46.51 |
| Q1 2026 | -33,247 | Sold Out | 0 | $0.00 |
| Q4 2025 | +3,232 | Add 10.77% | 33,247 | $49.70 |
| Q3 2025 | +30,015 | New Buy | 30,015 | $47.79 |
| Q4 2024 | -27,525 | Sold Out | 0 | $0.00 |
| Q3 2024 | +27,525 | New Buy | 27,525 | $31.18 |
| Q3 2023 | -27,769 | Sold Out | 0 | $0.00 |
| Q2 2023 | -16,137 | Reduce 36.75% | 27,769 | $30.06 |
| Q1 2023 | -36,801 | Reduce 45.60% | 43,906 | $0.04 |
| Q4 2022 | -11,050 | Reduce 12.04% | 80,707 | $0.04 |
| Q3 2022 | -19,426 | Reduce 17.47% | 91,757 | $33.85 |
| Q2 2022 | -16,894 | Reduce 13.19% | 111,183 | $28.92 |
| Q1 2022 | +41,964 | Add 48.73% | 128,077 | $32.32 |
| Q4 2021 | +17,516 | Add 25.53% | 86,113 | $29.16 |
| Q3 2021 | +57,797 | Add 535.16% | 68,597 | $26.66 |
| Q2 2021 | -34,329 | Reduce 76.07% | 10,800 | $30.83 |
| Q1 2021 | +45,129 | New Buy | 45,129 | $26.17 |
| Q2 2020 | -29,620 | Sold Out | 0 | $0.00 |
| Q1 2020 | -13,627 | Reduce 31.51% | 29,620 | $17.99 |
| Q4 2019 | +7,952 | Add 22.53% | 43,247 | $23.72 |
| Q3 2019 | -10,970 | Reduce 23.71% | 35,295 | $27.48 |
| Q2 2019 | +4,784 | Add 11.53% | 46,265 | $33.09 |
| Q1 2019 | +5,764 | Add 16.14% | 41,481 | $35.03 |
| Q4 2018 | +35,717 | New Buy | 35,717 | $33.23 |
| Q2 2017 | -10,548 | Sold Out | 0 | $0.00 |
| Q1 2017 | -17,029 | Reduce 61.75% | 10,548 | $31.29 |
| Q4 2016 | +12,777 | Add 86.33% | 27,577 | $25.24 |
| Q3 2016 | +300 | Add 2.07% | 14,800 | $24.73 |
| Q2 2016 | -5,800 | Reduce 28.57% | 14,500 | $20.34 |
| Q1 2016 | -26,700 | Reduce 56.81% | 20,300 | $15.27 |
| Q4 2015 | +13,400 | Add 39.88% | 47,000 | $13.45 |
| Q3 2015 | +8,700 | Add 34.94% | 33,600 | $14.02 |
| Q2 2015 | -18,087 | Reduce 42.08% | 24,900 | $16.99 |
| Q1 2015 | +29,021 | Add 207.80% | 42,987 | $12.10 |
| Q4 2014 | +13,966 | New Buy | 13,966 | $8.31 |
Paul Tudor Jones's Supernus Pharmaceuticals Investment FAQs
Paul Tudor Jones first purchased Supernus Pharmaceuticals, Inc. (SUPN) in Q4 2014, acquiring 13,966 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Supernus Pharmaceuticals, Inc. (SUPN) for 35 quarters since Q4 2014.
Paul Tudor Jones's largest addition to Supernus Pharmaceuticals, Inc. (SUPN) was in Q3 2021, adding 68,597 shares worth $1.83 M.
According to the latest 13F filing for Q2 2026, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 24,746 shares of Supernus Pharmaceuticals, Inc. (SUPN), valued at approximately $1.15 M.
As of the Q2 2026 filing, Supernus Pharmaceuticals, Inc. (SUPN) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Supernus Pharmaceuticals, Inc. (SUPN) was 128,077 shares, as reported at the end of Q1 2022.